摘要:
N-sulfamoyl-N′-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditions
摘要:
The present invention relates to the use of known and novel N-sulfamoyl-N′-arylpiperazines corresponding to Formula I and their physiologically compatible acid addition salts for the treatment or inhibition of obesity and related conditions.
摘要:
N-sulfamoyl-N′-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditions.
摘要:
The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions.
摘要:
The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions.
摘要:
3-cyanonaphthalene-1-carboxylic acid perhydroxyalkylmethyl-piperazine compounds of formula I which are antagonistic to tachykinin receptors, pharmaceutical compositions containing such compounds, methods of using such compounds for the treatment and/or inhibition of various diseases and disorders, processes for preparing such piperazine compounds, and intermediate products of these processes.
摘要:
3-cyanonaphthalene-1-carboxylic acid perhydroxyalkylmethyl-piperazine compounds of formula I which are antagonistic to tachykinin receptors, pharmaceutical compositions containing such compounds, methods of using such compounds for the treatment and/or inhibition of various diseases and disorders, processes for preparing such piperazine compounds, and intermediate products of these processes.
摘要:
Compounds having fibrinogen receptor-antagonistic activity, of the general formula I ##STR1## in which Z is oxygen or a methylene group, B is a phenyl or pyridyl radical, R.sup.1 is hydrogen or a group forming a biolabile ester, and their physiologically acceptable acid addition salts and physiologically acceptable salts of acids of formula I.
摘要:
N-triazolylmethyl-piperazine compounds which exhibit neurokinin receptor antagonistic activity corresponding to the formula I: wherein R1, R2 and R3 have the meanings given in the specification; pharmaceutical compositions containing these compounds; a process for preparing these compounds, and intermediate products of this process.
摘要:
The invention relates to a cryogenic storage device and to a method for operating a cryogenic storage device, particularly for cryogenic storage of biological samples, comprising a sample carrying device that is set up to accommodate samples, a cryogenic container that is set up to accommodate the sample carrying device, a container cooling device with which the cryogenic container can be cooled, an intermediate storage container that is set up for intermediate storage of the sample carrying device, a transport device with which the sample carrying device can be moved between the cryogenic container and the intermediate storage container and a sensor device with which at least one operating parameter of the cryogenic storage device can be registered. The transport device is set up to be activated in dependence on an output signal from the sensor device upon registering a predetermined operating condition of the cryogenic storage device, so that the sample carrying device is moved from the cryogenic container to the intermediate storage container. Additionally or alternatively, an intermediate storage cooling device that is set up for cooling the intermediate storage container can be activated in dependence on an output signal of the sensor device.